Detalhe da pesquisa
1.
The Evolutionary Pathway to Virulence of an RNA Virus.
Cell
; 169(1): 35-46.e19, 2017 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28340348
2.
Experimental Evolution to Study Virus Emergence.
Cell
; 169(1): 1-3, 2017 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28340335
3.
Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3.
Nature
; 619(7968): 135-142, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37316671
4.
Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
Lancet
; 403(10432): 1164-1175, 2024 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402887
5.
Two-Year Duration of Immunity of Inactivated Poliovirus Vaccine: A Follow-up Study in Pakistan in 2020.
J Infect Dis
; 229(1): 39-42, 2024 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37368349
6.
Impact of Supplementary Immunization Activities using Novel Oral Polio Vaccine Type 2 during a Large outbreak of Circulating Vaccine-Derived Poliovirus in Nigeria.
J Infect Dis
; 229(3): 805-812, 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37357964
7.
Modeling Poliovirus Transmission and Responses in New York State.
J Infect Dis
; 229(4): 1097-1106, 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37596838
8.
Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022.
Emerg Infect Dis
; 30(4): 775-778, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38526214
9.
Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial.
Lancet
; 401(10371): 131-139, 2023 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495882
10.
Progress Toward Poliomyelitis Eradication - Worldwide, January 2022-December 2023.
MMWR Morb Mortal Wkly Rep
; 73(19): 441-446, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38753550
11.
Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine.
BMC Infect Dis
; 24(1): 535, 2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38807038
12.
Circulating vaccine derived polio virus type 2 outbreak and response in Yemen, 2021-2022, a retrospective descriptive analysis.
BMC Infect Dis
; 24(1): 321, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38491425
13.
Polio endgame finish is in sight.
Nature
; 619(7968): 36-38, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37316591
14.
Effective partnership and in-country resource mobilization in Sudan for cVDPV2 outbreak response amid multiple emergencies in 2020-2021.
BMC Public Health
; 24(1): 235, 2024 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38243167
15.
Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.
Risk Anal
; 44(2): 366-378, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37344934
16.
Worst-case scenarios: Modeling uncontrolled type 2 polio transmission.
Risk Anal
; 44(2): 379-389, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37344376
17.
Observational analysis of the immunogenicity and safety of various types of spinal muscular atrophy vaccines.
Inflammopharmacology
; 32(2): 1025-1038, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38308795
18.
Impact of COVID -19 on expanded programme on Immunisation in District Dir lower Khyber Pakhtunkhwa.
J Pak Med Assoc
; 74(3): 456-458, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38591277
19.
The Origins and Risk Factors for Serotype-2 Vaccine-Derived Poliovirus Emergences in Africa During 2016-2019.
J Infect Dis
; 228(1): 80-88, 2023 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36630295
20.
Co-administration of Oral Cholera Vaccine With Oral Polio Vaccine Among Bangladeshi Young Children: A Randomized Controlled Open Label Trial to Assess Interference.
Clin Infect Dis
; 76(2): 263-270, 2023 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36136760